Multi-site, multi-platform clinical oncology trials seek to enhance quantitative utility of the apparent diffusion coefficient (ADC) metric by reducing technical cross-platform variability due to systematic gradient nonlinearity (GNL). Here we test feasibility of retrospective GNL correction implementation for a representative subset of subjects and systems from the ACRIN6698 breast cancer therapy response trial. GNL ADC correction based on previously developed formalism is demonstrated for trace-DWI DICOM using system-specific gradient-channel fields derived from vendor-provided spherical harmonic tables. Implemented correction substantially improves precision and removes ADC bias for DWI QC phantoms, and markedly changes ADC histogram percentiles for solid breast tumors.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords